ENDP - Endo International plc
| Previous Close | 4.8200 |
| Open | 4.9500 |
| Bid | 4.8200 x 34100 |
| Ask | 4.8900 x 27000 |
| Day's Range | 4.8100 - 5.0700 |
| 52 Week Range | 1.9700 - 12.4900 |
| Volume | 5398371 |
| Avg. Volume | 9,107,888 |
| Market Cap | 1.1B |
| Beta (3Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2000 |
| Earnings Date | Feb 26, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.78 |
- Zacks
Why Is Endo (ENDP) Up 12.3% Since Last Earnings Report?
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Options Traders Expect Huge Moves in Endo (ENDP) Stock
Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.
- Zacks
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
- Zacks
BioDelivery's Belbuca Sales & Symproic Addition Encouraging
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
- Zacks
Fed Reportedly Opens Criminal Investigation on Opioid Makers
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
- MarketWatch
Shares of opioid makers and distributors drop on criminal probe
Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources. Six companies have disclosed in regulatory filings that they have received grand-jury subpoenas from the U.S. attorney's office in the Eastern District of New York, according to the report. Teva Pharmaceutical Industries Ltd. is down 8%, Mallinckrodt 5%, Amneal Pharmaceuticals Inc. 10%, and Johnson & Johnson 1%. Shares of cited wholesale drug distributors also declined, AmerisourceBergen by 3% and McKesson by 5%. In addition, shares of companies facing opioid litigation but not cited in the Journal story also dropped, with Endo International down 9% and Cardinal Health 4%. In recent weeks, the stocks of these companies have rallied as investors took the view that the possibility of global settlement that would resolve all pending and future litigation was a positive.
- MarketWatch
Shares of generic drugmakers rise on hope that legal issues are nearing an end
Shares of generic drugmakers jumped Monday as speculation mounts about a series of legal settlements potentially nearing a resolution.
- MarketWatch
Shares of generic drugmakers jump in morning trading
Shares of generic drugmakers are up in morning trading, with Mallinckrodt leading the pack as its stock rallied 15%. Teva Pharmaceutical Industries Ltd. is up 5%, Mylan up 4% and Endo International 4%. Bloomberg reported Monday morning that sources have said Teva and other drugmakers, including Sun Pharmaceutical Industries, are in talks with the Department of Justice to resolve allegations of price-fixing in the generic drug market. Separately, SVB Leerink analysts said this week that if plans for Endo, Mallinckrodt and Teva to enter into a "global opioid settlement framework" with state attorneys general go through, likely in the fourth quarter of 2019 or the first quarter of 2020, it would be a positive for those companies. "We could also see read-through for other opioid-levered names like Endo and Mallinckrodt," the analysts wrote in a Nov. 24 note.
- CNW Group
Endo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference
Endo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference
- Zacks
Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA
The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.
- Benzinga
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...
- GuruFocus.com
Teva, Bausch Could Be Next to File for Bankruptcy
The number of pharmaceutical and biotechnology companies seeking Chapter 11 protection has nearly tripled the 10-year average in 2019 and is expected to continue to rise Continue reading...
- CNW Group
Endo Announces FDA's Acceptance of Original Biologics License Application (BLA) for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
Endo Announces FDA's Acceptance of Original Biologics License Application (BLA) for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
- Simply Wall St.
Imagine Owning Endo International (NASDAQ:ENDP) And Trying To Stomach The 94% Share Price Drop
It is doubtless a positive to see that the Endo International plc (NASDAQ:ENDP) share price has gained some 78% in the...
- Zacks
BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View
BioDelivery (BDSI) beats earnings and sales expectations in the third quarter of 2019. The company raises its 2019 revenue guidance.
- Thomson Reuters StreetEvents
Edited Transcript of ENDP earnings conference call or presentation 5-Nov-19 12:30pm GMT
Q3 2019 Endo International PLC Earnings Call
- MarketWatch
Endo CEO to step down when successor is named
Endo International said this week that Paul Campanelli, president and CEO, will step down when a successor is named. A successor has not yet been appointed. Campanelli, who took over the top job at Endo in 2016, has been named board chairman. "We're going to need somebody that can look across multiple segments and also medical aesthetics," Campanelli told investors on Tuesday. Endo's stock is down $43.15 year-to-date, while the S&P 500 has climbed about 23%.
- American City Business Journals
Endo begins search for a new CEO
The specialty pharmaceuticals company's chief executive will stay in the post until his successor is named.
- Zacks
Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y
Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.
- ACCESSWIRE
Endo International Plc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2019 / Endo International Plc (NASDAQ: ENDP ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on November 5, 2019 at 7:30 ...
- Zacks
Endo International (ENDP) Q3 Earnings and Revenues Top Estimates
Endo (ENDP) delivered earnings and revenue surprises of 13.21% and 3.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
